The Accounts Companies House intelligence

ASTELLAS PHARMA EUROPE LTD.

#02486792 · Active · Incorporated 1990-03-29 (36y 2m) · Last filing 2026-02-10 (3mo ago)
Consumer Discretionary · SIC 46460 · G Wholesale & Retail Trade; Repair of Motor Vehicles · Full accounts

Get an alert when ASTELLAS PHARMA EUROPE LTD. files next

Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.

Free · confirmation link first · unsubscribe in one click

Next accounts due

2026-12-31 (in 7mo)

Last filed for 2025-03-31

Confirmation statement due

2027-02-01 (in 9mo)

Last made up 2026-01-18

Watchouts

None on the register

Cash

—

Latest balance sheet

Net assets

£361M

-40.3% vs 2024

Employees

—

Average over period

Profit before tax

£270M

+115.8% vs 2024

Name history

Renamed 2 times since incorporation

  1. ASTELLAS PHARMA EUROPE LTD. 2005-05-03 → present
  2. YAMANOUCHI U.K. LIMITED 1990-05-29 → 2005-05-03
  3. LUPINBROOK LIMITED 1990-03-29 → 1990-05-29

Accounts

2-year trend · latest reflected 2025-03-31

Metric Trend 2024-03-312025-03-31
Turnover £1,698,795,943£2,151,447,642
Operating profit £15,182,039£128,813,280
Profit before tax £124,985,264£269,707,871
Net profit £114,086,338£243,652,913
Cash ——
Total assets less current liabilities £604,618,585£361,086,165
Net assets £604,618,585£361,086,165
Equity £604,618,585£361,086,165
Average employees ——
Wages £69,642,857£88,735,264

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Ratios

Computed from the line items above — sparklines read oldest → newest

Ratio Trend 2024-03-312025-03-31
Operating margin 0.9%6.0%
Net margin 6.7%11.3%
Return on capital employed 2.5%35.7%
Current ratio 1.37x1.16x
Interest cover 72.98x177.54x

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Audit & accounting basis

Accounting basis
Other
Reporting scope
Standalone (parent only)
Auditor
Ernst & Young
Audit opinion
Unqualified (clean)
Going concern
Affirmed

“The Company's financial statements are prepared using the going concern basis of accounting. The Company has continued to see a sales performance in the year whereby the pipeline remains strong and are projecting sales to remain strong in coming years based upon affiliate sales to market, as well as relevant market share.”

Group structure

  1. ASTELLAS PHARMA EUROPE LTD. · parent
    1. Astellas Pharma S.A.S. 100% · France
    2. Astellas Pharma Ges.m.b.H. 100% · Austria
    3. Astellas Pharma S.R.O. 80% · Czechia
    4. Astellas Pharma GmbH 100% · Germany
    5. Astellas Pharma S.A. 75% · Spain
    6. Astellas Pharmaceuticals AEBE 99.99% · Greece
    7. Astellas Pharma Kft. 100% · Hungary
    8. Astellas Pharma Co. Ltd. 100% · Ireland
    9. Astellas Pharma S.p.A. 94.96% · Italy
    10. Astellas Pharma A/S 100% · Denmark
    11. Astellas Farma Limitada 99.99% · Portugal
    12. Astellas Pharma AB 100% · Sweden
    13. Astellas Pharma Sp.z.o.o. 100% · Poland
    14. Astellas Pharma EOOD 100% · Bulgaria
    15. Astellas Pharma Ltd. 100% · United Kingdom
    16. Astellas d.o.o., Croatia 100% · Croatia
    17. Astellas Pharma S.r.l. 99.93% · Romania
    18. Astellas Pharma Slovenia 100% · Slovenia
    19. Astellas Engineered Small Molecules U.K. Limited 100% · United Kingdom
    20. Astellas Pharma Capability Centre Poland Sp. Z o.o. 100% · Poland

Significant events

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

People

5 active · 65 resigned

Name Role Appointed Born Nationality
DEMPSEY, Martina Mary, Ms. Director 2023-04-01 Dec 1965 Irish
FLOWERDEW, Lesley Ann Director 2022-04-01 Oct 1967 British
GANE, Richard Hugh Director 2021-11-15 Mar 1969 British
MORTLOCK, Andrew Austen, Dr. Director 2025-05-24 Dec 1965 British
SCHADDELEE, Marloes Petra Director 2022-07-01 Nov 1972 Dutch
Show 65 resigned officers
Name Role Appointed Resigned
ABE, Yasuhide Secretary — 1994-10-01
HATANAKA, Kazuyoshi Secretary 2003-06-27 2007-01-11
HINCHLIFFE, Sally Anne Secretary 2014-04-25 2025-06-20
IMANISHI, Masayuki Secretary 2007-01-11 2008-04-07
KATOGI, Yoshio Secretary 1998-08-01 1999-04-01
NAKAJIMA, Hajime Secretary 1999-10-01 2002-04-01
TANAKA, Akihiro, Dr Secretary 2002-04-01 2003-08-01
TSCHUDIN, Jean-Charles Secretary 2003-06-27 2003-06-28
UCHIYAMA, Hirokatsu Secretary 1994-10-01 1998-09-04
YAMAMOTO, Hirokazu, Dr Secretary 1998-11-06 1999-10-01
ABE, Yasuhide Director — 1994-10-01
BOHNER, Jochen Norbert Director 2018-07-06 2020-12-17
CHIHARA, Osamu Director 2012-04-20 2012-06-19
CUNHA DE PAULA, Thais, Ms. Director 2020-12-17 2022-03-31
HARA, Hiromu, Dr Director 1997-08-01 1998-09-04
HARFORD, Joseph Francis Director — 1998-01-15
HATANAKA, Kazuyoshi Director 2003-06-27 2005-07-22
HATANAKA, Yoshihiko Director 2005-05-26 2006-04-01
HIRANO, Masaaki Director 2018-04-01 2020-12-17
IIZUKA, Hisakazu Director — 1993-06-29
ISHII, Yasuo Director 2001-01-01 2008-03-31
JANSEN VAN RENSBURG, Eugene Theodorus Director 2015-07-20 2018-07-06
JONES, Kenneth Wade Director 2011-04-01 2016-02-25
KATOGI, Yoshio Director 1998-08-01 1999-04-01
KAWAISHI, Kiyoshi Director 2001-01-01 2002-07-01
KIMURA, Kaoru Director 1998-08-01 2000-08-02
KOBAYASHI, Yohshi Director 1996-08-01 1998-09-04
KOSCHE, Dirk Armin, Dr Director 2018-07-06 2021-12-31
LAMBERT, Keith Philip Director 2021-04-01 2023-05-31
MASUDA, Yasumasa Director 2009-04-01 2012-04-19
MATSUI, Hidefumi Director 1995-11-01 1997-08-01
MATSUI, Yukio Director 2016-04-01 2018-07-06
MATSUI, Yukio Director 2007-11-01 2012-04-17
MATSUMOTO, Junichiro Director 1993-06-29 1996-08-01
MCDOUGALL, Alan, Dr Director 2023-09-01 2025-03-31
MIYAKE, Masatoshi Director 2006-04-01 2008-05-01
MORIOKA, Shigao Director — 1996-08-01
NAKAJIMA, Hajime Director 1999-10-01 2002-04-01
NOGAWA, Hiroshi Director 2012-04-01 2013-09-30
NOGAWA, Hiroshi Director 2007-10-11 2009-04-01
NOGAWA, Hiroshi Director 2004-06-01 2005-07-22
OKAMURA, Naoki Director 2016-04-01 2018-04-01
ONODA, Masayoshi Director — 1996-08-01
PEARSON, Adam John Director 2020-04-01 2022-06-30
SAITOH, Ken-Ichiro Director — 1996-05-13
SAKAE, Yasuo Director 2013-10-01 2016-04-01
SCHULZE, Daniel Benjamin Matthias Director 2016-04-04 2021-11-14
SHIMAMOTO, Kentaro Director 2023-06-02 2023-08-31
STANDER, Nicolaas Jacobus Director 2015-03-10 2015-07-20
TAKAHASHI, Shigekazu Director 2000-04-01 2001-01-01
TAKAYAMA, Mitsuyoshi Director 2005-05-26 2007-10-11
TAKEDA, Chikashi Director 2012-06-20 2017-03-31
TAMURA, Toshinari, Dr Director 2002-07-01 2003-06-27
TANAKA, Akihiro, Dr Director 2002-04-01 2003-08-01
TEMKO, Jerrold Howard Director 2015-03-10 2016-02-22
TSCHUDIN, Jean-Charles Director 2003-06-27 2004-04-30
UCHIYAMA, Hirokatsu Director 1994-10-01 1998-09-04
UEDA, Hidehiko Director 2000-08-01 2001-01-01
YAMAMOTO, Hirokazu, Dr Director 1998-08-01 2000-04-01
YAMAZAKI, Atsuki Director 2005-05-26 2006-04-01
YOKOTA, Chihiro Director 2005-05-26 2009-10-29
YOSHIDA, Masao Director 2008-04-01 2011-04-01
YOSHIDA, Masao Director 2006-04-01 2007-10-31
YOSHIMITSU, Toru Director 2017-04-01 2020-03-31
ZIELER, Claus Gerhard Director 2022-01-01 2023-03-31

Ownership

Persons with significant control

Name Kind Nature of control Notified Status
Astellas Pharma Inc. Corporate entity Shares 75–100%, Voting 75–100%, Appoints directors 2016-04-06 Ceased 2023-02-24

Filing timeline

Last 20 of 253 total filings

Material constitutional events — rename, articles re-file, resolution

  • 2025-03-04 RESOLUTIONS Resolution
Date Type Category Description
2026-02-10 CS01 confirmation-statement Confirmation statement with no updates PDF
2026-02-10 ANNOTATION
2026-02-10 RP01AP01 officers Replacement filing of director appointment with name PDF
2025-10-09 AA accounts Accounts with accounts type full
2025-06-29 TM02 officers Termination secretary company with name termination date PDF
2025-05-27 AP01 officers Appoint person director company with name date PDF
2025-04-03 TM01 officers Termination director company with name termination date PDF
2025-03-04 SH19 capital Capital statement capital company with date currency figure
2025-03-04 SH20 capital Legacy
2025-03-04 CAP-SS insolvency Legacy
2025-03-04 RESOLUTIONS resolution Resolution
2025-01-20 CS01 confirmation-statement Confirmation statement with no updates PDF
2024-12-16 AA accounts Accounts with accounts type full
2024-01-18 CS01 confirmation-statement Confirmation statement with no updates PDF
2023-10-03 AA accounts Accounts with accounts type full
2023-09-08 AP01 officers Appoint person director company with name date PDF
2023-09-04 TM01 officers Termination director company with name termination date PDF
2023-06-09 AP01 officers Appoint person director company with name date PDF
2023-06-07 TM01 officers Termination director company with name termination date PDF
2023-04-06 AP01 officers Appoint person director company with name date PDF

Public-record activity

Raw counts from Companies House — last 12–24 months

Filings
6

last 12 months

Capital events
2

last 24 months

Officers appointed
1

last 12 months

Officers resigned
1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

Year-on-year

FY2024 → FY2025 · period ending 2025-03-31 vs 2024-03-31

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Official Companies House page